PAPSS2 and polycystic ovary syndrome: The few patients identified with mutations in this gene are female, and heterozygous inactivation of PAPSS2 has been associated with polycystic ovary syndrome, premature puberty, hyperandrogenic anovulation, very low DHEA-S levels, and increased androgen levels (43).